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Abstract
Background: Patients with locally advanced esophageal cancer who are treated with trimodality therapy have a
high recurrence rate. Preclinical evidence suggests that inhibition of cyclooxygenase 2 (COX2) increases the
effectiveness of chemoradiation, and observational studies in humans suggest that COX-2 inhibition may reduce
esophageal cancer risk. This trial tested the safety and efficacy of combining a COX2 inhibitor, celecoxib, with
neoadjuvant irinotecan/cisplatin chemoradiation.
Methods: This single arm phase 2 trial combined irinotecan, cisplatin, and celecoxib with concurrent radiation therapy.
Patients with stage IIA-IVA esophageal cancer received weekly cisplatin 30 mg/m2 plus irinotecan 65 mg/m2 on weeks
1, 2, 4, and 5 concurrently with 5040 cGy of radiation therapy. Celecoxib 400 mg was taken orally twice daily during
chemoradiation, up to 1 week before surgery, and for 6 months following surgery.
Results: Forty patients were enrolled with stage IIa (30 %), stage IIb (20 %), stage III (22.5 %), and stage IVA (27.5 %)
esophageal or gastroesophageal junction cancer (AJCC, 5th Edition). During chemoradiation, grade 3–4 treatment-
related toxicity included dysphagia (20 %), anorexia (17.5 %), dehydration (17.5 %), nausea (15 %), neutropenia (12.5 %),
diarrhea (10 %), fatigue (7.5 %), and febrile neutropenia (7.5 %). The pathological complete response rate was 32.5 %.
The median progression free survival was 15.7 months and the median overall survival was 34.7 months. 15 % (n = 6)
of patients treated on this study developed brain metastases.
Conclusions: The addition of celecoxib to neoadjuvant cisplatin-irinotecan chemoradiation was tolerable; however,
overall survival appeared comparable to prior studies using neoadjuvant cisplatin-irinotecan chemoradiation alone.
Further studies adding celecoxib to neoadjuvant chemoradiation in esophageal cancer are not warranted.
Trial registration: Clinicaltrials.gov: NCT00137852, registered August 29, 2005.
Keywords: Esophageal cancer, Neoadjuvant therapy, Chemoradiation, Cyclooxygenase 2 inhibition
* Correspondence: peter_enzinger@dfci.harvard.edu
1Center for Esophageal and Gastric Cancer, Dana-Farber Brigham and
Women’s Cancer Center and Gastrointestinal Cancer Center, Department of
Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School,
450 Brookline Ave, Boston, MA 02215, USA
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cleary et al. BMC Cancer  (2016) 16:468 
DOI 10.1186/s12885-016-2485-9
Background
Locally advanced esophageal cancer is an aggressive ma-
lignancy with a high recurrence rate [1]. Meta-analyses
of neoadjuvant chemoradiation trials suggest that there
is a survival benefit for patients treated with neoadjuvant
chemoradiation and surgery compared to patients
undergoing surgery alone [2, 3]. Moreover, multiple
studies have reported that pathological complete re-
sponse after neoadjuvant chemoradiation predicts in-
creased survival [4–7].
Two prior randomized clinical trials testing neoadju-
vant radiotherapy with cisplatin and 5-FU followed by
surgery demonstrated a survival benefit compared to pa-
tients treated with surgery alone [8, 9]. Recently, the
CROSS trial demonstrated a significant survival benefit
for neoadjuvant radiotherapy with carboplatin and pacli-
taxel followed by surgery when compared to surgery
alone, rendering this regimen as a widely used standard
of care. Patients treated on the CROSS trial had a me-
dian overall survival of 49 months and a pathological
complete response rate of 29 % [10].
Cisplatin/irinotecan is an active regimen in advanced
esophageal cancer [11, 12]. Neoadjuvant chemoradiation
with cisplatin/irinotecan has also been evaluated in two
phase 2 studies. Both trials reported a 16 % pathological
complete response rate; median survival was 31.7 and
36 months, respectively [13, 14]. The major toxicities of
cisplatin/irinotecan and radiation therapy were myelo-
suppression, esophagitis, and diarrhea. While there have
been multiple trials testing neoadjuvant chemoradiother-
apy prior to surgery compared to surgery alone in locally
advanced esophageal cancer, there are no trials compar-
ing chemotherapy combinations to use with radiation
and thus there is no one standard backbone regimen to
incorporate in trials with targeted therapies.
Several lines of study suggest that non-steroidal anti-
inflammatory (NSAID) medications modify the natural
history of selected gastrointestinal malignancies and that
inhibition of cyclooxygenase 2 (COX2) plays an import-
ant role in this effect. In colorectal cancer, aspirin and
NSAIDs appear to increase survival and decrease the
risk of cancer development and recurrence [15–19]. In-
creased COX2 expression in esophageal cancer has also
been associated with decreased survival and is thought
to play a role in promoting the progression from Bar-
rett’s esophagus to esophageal adenocarcinoma [20–24].
Several preclinical studies have shown that the selective
COX2 inhibitor celecoxib works synergistically with ra-
diation to increase cancer cell death and high expression
of COX2 correlates with decreased response to radiation
[25–29].
Based on these data, we conducted a phase II trial of
celecoxib in conjunction with neoadjuvant radiation
therapy and concurrent cisplatin plus irinotecan in




This phase 2 clinical trial (NCT00137852) was a single
arm study evaluating the efficacy and safety of periopera-
tive celecoxib and neoadjuvant chemoradiation with
weekly cisplatin plus irinotecan followed by surgery in
locally advanced esophageal and gastroesophageal junc-
tion cancer patients.
Study population
This trial was open to patients with stage IIA, IIB, III,
IVA esophageal or gastroesophageal junction cancer by
5th American Joint Committee on Cancer (AJCC) [30].
Both adenocarcinoma and squamous cell carcinoma his-
tologies were permissible. All patients underwent staging
workup with a CT scan of the chest, abdomen and pelvis
with intravenous and oral contrast. Patients also under-
went a mandatory upper endoscopy with endoscopic
ultrasound and bone scan. Most patients were also eval-
uated with either a positron emission tomography (PET)
scan (21 patients) or single-photon emission computed
tomography (SPECT) scan (7 patients).
Prior chemotherapy, surgery, or radiation therapy for
esophageal cancer was not allowed. Other eligibility criteria
included an adequate performance status (Eastern
Cooperative Oncology Group Performance Status ≤1), a
serum creatinine ≤ 1.5 mg/dL, serum bilirubin ≤ 1.5 mg/dL,
and aspartamine transaminase ≤ 3 times the upper limit of
normal. Patients were ineligible if they had a history of prior
severe reaction to nonsteroidal anti-inflammatory drugs
(NSAIDs) or sulfonamides or had significant comorbidities
that made chemoradiation inadvisable. Patients with an-
other active malignancy, Gilbert’s Disease, interstitial pul-
monary fibrosis, seizure disorder requiring anti-epileptics,
uncontrolled diarrhea, symptomatic hearing loss, and grade
2–4 neuropathy were also excluded.
This trial was approved by the Internal Review Board
(IRB) of the Dana-Farber/Harvard Cancer Center. All
patients signed an IRB-approved consent prior to
enrollment.
Treatment plan
All patients were scheduled to receive neoadjuvant che-
moradiation, perioperative celecoxib, and surgery.
Neoadjuvant therapy consisted of external beam radi-
ation (5040 cGy) delivered in 28 fractions over 5.5 weeks
along with intravenous cisplatin 30 mg/m2 and irinote-
can 65 mg/m2 on weeks 1, 2, 4, and 5. Patients started
celecoxib 400 mg by mouth twice daily 3 days prior to
initiation of chemoradiation and stopped 1 week before
surgery. Surgery was performed 4 to 8 weeks following
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the completion of chemoradiation. An esophagectomy
was performed according to normal standard of care
practices at Brigham and Women’s Hospital or at
Massachusetts General Hospital. Celecoxib was restarted
at the same dose and schedule upon discharge from the
hospital following esophagectomy. Patient then contin-
ued celecoxib for 26 weeks.
Study design and assessments
Toxicity assessments were made according to the National
Cancer Institute’s common toxicity scale (Version 1.0) and
the RTOG Radiation Morbidity Scoring Criteria.
Cisplatin was dose reduced by 50 % if the serum cre-
atinine was between 1.7 and 2.0 mg/dL. Cisplatin was
temporarily stopped and subsequently dose reduced by
50 % for a serum creatinine > 2.0 mg/dL, grade 3–4
ototoxicity, and grade 3–4 neuropathy. Irinotecan was
held and subsequently dose reduced to 50 mg/m2 for
an absolute neutrophil count (ANC) <1000/mm3, plate-
lets <75,000/mm3, grade 3–4 diarrhea, and grade 4 fa-
tigue. If treatment parameters were not met for either
cisplatin or irinotecan, treatment with both chemother-
apy drugs was interrupted. Radiation was temporarily
stopped for ANC <1000/mm3, platelets <50,000/mm3,
any grade 4 toxicity, and grade 3 esophagitis/mucositis.
Radiation was also postponed in instances where irino-
tecan/cisplatin was held for ≥ 2 weeks. Celecoxib was
held for any grade 4 toxicity, grade 3 gastric or duo-
denal ulcers, vomiting, or bleeding.
Statistical analyses
The primary objective of this trial was to determine the
pathological complete response rate and the toxicities of
the chemoradiation regimen. A pathological complete
response was defined as the absence of tumor cells in
the esophagectomy specimen. Our analysis defined
tumor downstaging as a decrease in the stage seen on
pathological staging following esophagectomy compared
to the stage determined during pretreatment staging
workup.
The trial had a two-stage design. In the first stage, if
at least 3 of 17 patients had a pathological complete re-
sponse, the second stage of patients was allowed to en-
roll. A pathological complete response rate of 25 % was
chosen as a benchmark that would be promising in this
population because, at the time of the study design, this
was the approximate average pathological complete re-
sponse rate seen on combined modality trials. The
study population of 40 patients was selected because
the probability that the combination would be consid-
ered promising was 80 % if the true complete patho-
logical response rate was 25 %. In addition, a study
population of 40 patients was selected because the
90 % confidence interval on any toxicity rate would be
no wider than 30 percentage points and the chance of
observing one or more rare (5 % incidence) toxicities
was greater than 83 %.
Secondary objectives of the protocol included measur-
ing the median overall survival and median progression
free survival. Progression free survival and overall sur-
vival were determined by the Kaplan-Meier method.
Both progression free survival and overall survival were
analyzed with an intention to treat analysis. Overall sur-
vival was calculated as the time from enrollment until
death, and progression free survival as the time until dis-
ease progression or death. Survival calculations based on
pathological staging, measured the amount time from
surgery until progression of disease or death.
Results
Baseline patient characteristics
From January 2002 until September 2005, 40 patients
with locally advanced esophageal or gastroesophageal
junction cancer were enrolled. Baseline characteristics of
patients enrolled in the study are shown in Table 1. The
median age was 65 years and the majority of patients
were male (85 %). Eighty-five percent of the patients had
adenocarcinoma pathology. Most of the tumors were
Table 1 Baseline Patient Characteristics
Characteristic Total (N = 40)
Age
Median 65 years
Range 37 to77 years
Gender
Male 34 (85 %)
Female 6 (15 %)
Performance Status
ECOG 0 19 patients (48 %)
ECOG 1 21 patients (52 %)
Pathology
Adenocarcinoma 34 patients (85 %)
Squamous carcinoma 6 patients (15 %)
Stage (AJCC 5th edition)
Stage IIA 12 patients (30 %)
Stage IIB 8 patients (20 %)
Stage III 9 patients (22.5 %)
Stage IVA 11 patients (27.5 %)
Tumor Location
Middle Esophagus 7 patients (17.5 %)
Lower Esophagus 23 patients (57.5 %)
Gastroesophageal Junction 10 patients (25 %)
Dysphagia (Grade ≥1) 34 patients (85 %)
Greater than 10 % weight loss 10 patients (25 %)
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located in either the distal esophagus (57.5 %) or gastro-
esophageal junction (25 %). Preoperative staging showed
that 30 % of tumors were stage IIA, 20 % stage IIB,
22.5 % stage III, and 27.5 % stage IVA (AJCC, 5th
Edition).
Treatment duration and toxicities
All 40 patients initiated treatment with neoadjuvant che-
moradiation and celecoxib. Toxicity assessment and effi-
cacy analyses were performed on all 40 patients. There
were no treatment-related deaths during chemoradia-
tion. Four patients (10 %) discontinued protocol therapy
after 2 to 3 weeks due to treatment-related toxicity. One
of these patients developed febrile neutropenia and sep-
sis. The other three patients had severe dehydration sec-
ondary to severe nausea and/or diarrhea. In addition,
one patient could not complete his chemoradiation fol-
lowing the development of a paraneoplastic neurologic
syndrome associated with anti-Yo antibodies and was
taken to surgery early. During chemoradiation, four pa-
tients (10 %) required a radiation delay and five patients
(12.5 %) required chemotherapy dose reduction, primar-
ily for neutropenia and diarrhea.
Grade 3 and 4 toxicities observed during chemoradia-
tion are listed in Table 2. The most common treatment-
related grade 3–4 toxicities were dysphagia (20 %), an-
orexia (17.5 %), dehydration (17.5 %), nausea (15 %),
neutropenia (12.5 %), diarrhea (10 %), and fatigue
(7.5 %). Three patients (7.5 %) developed febrile
neutropenia.
Surgery
After completion of chemoradiation, one patient did not
undergo surgery because of progressive disease and a
second patient was deemed surgically unresectable. Of
the 38 patients who proceeded to esophagectomy, 23
patients (60.5 %) received a 3-hole esophagectomy, 7
patients completed an Ivor Lewis esophagectomy
(18.4 %), 5 patients underwent a transhiatal esophagec-
tomy (13.1 %), and 3 patients had a thoracoabdominal
esophagectomy (7.8 %).
Following surgery, patients were hospitalized for a me-
dian of 11 days (range 7 to 62 days). Eight patients
(21 %) were hospitalized for more than 14 days. One
patient developed an anastomotic leak and died from re-
spiratory failure 59 days after esophagectomy. Two pa-
tients died of sepsis 61 days and 137 days after
esophagectomy. In addition to these three deaths, two
patients developed a chylothorax that required surgical
repair.
Pathologic response and survival assessment
Thirteen out of the 40 patients (32.5 %) had a pathologic
complete response (Table 3). Another 15 % of patients
had microscopic residual disease. Tumor downstaging
occurred in 65 % of the 40 patients enrolled in the study.
Thirty-five of the thirty eight patients (92.1 %) who
underwent esophagectomy had an R0 resection.
All 40 patients were assessed according to an intention
to treat analysis. One patient was lost to follow-up at
3.9 years after enrollment. Patients enrolled in the trial
had a median progression free survival of 15.7 months
(95 % confidence interval (CI), 11.0 to 29.3 months) and
a median survival of 34.7 months (95 % CI, 19.0 to
Table 2 Treatment-Related Preoperative Grade 3 or 4 Adverse
Events
Adverse Event Grade 3 Grade 4
Hematologic
Leukopenia 6 (15.0 %) 2 (5.0 %)
Neutropenia 3 (7.5 %) 2 (5.0 %)
Anemia requiring blood transfusion 2 (5.0 %)
Febrile neutropenia 1 (2.5 %) 2 (5.0 %)
Thrombocytopenia 1 (2.5 %)
Gastrointestinal
Dysphagia, esophagitis, odynophagia 7 (17.5 %) 1 (2.5 %)
Anorexia 7 (17.5 %)
Dehydration 7 (17.5 %)
Nausea 6 (15.0 %)
Diarrhea 4 (10.0 %)
Vomiting 4 (10.0 %)
Abdominal pain or cramping 2 (5.0 %)
Systemic
Fatigue 3 (7.5 %)
Hypotension 3 (7.5 %) 1 (2.5 %)
Hyperbilirubinemia 1 (2.5 %)
Creatinine Elevation 1 (2.5 %)
Chest pain (non-cardiac) 1 (2.5 %)
Supraventricular arrhythmia 1 (2.5 %)
Syncope 1 (2.5 %)
Thrombosis/embolism 1 (2.5 %)
Table 3 Pathological Staging after Surgery
Stage Total 40 Patients
Complete Response 13 patients (32.5 %)
Microscopic Residual Disease 6 patients (15 %)
Stage I 3 patients (7.5 %)
Stage IIA 4 patients (10 %)
Stage IIB 4 patients (10 %)
Stage III 5 patients (12.5 %)
Stage IVA 3 patients (7.5 %)
Stage IVB or Refused Surgery 2 patients (5 %)
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44.5 months) (Fig. 1). The three-year survival rate was
47.5 % (95 % CI, 31.6–61.8 %) and the five-year survival
rate was 30 % (95 % CI, 18.6–46.8 %). Three deceased
patients had no evidence of esophageal cancer recur-
rence and died of causes other than esophageal cancer
(stroke, pneumonia, and colon cancer).
Figure 2 shows the Kaplan-Meier curves of clinical pre-
treatment stage specific survival rates. Preoperative clinical
stage was not predictive of overall survival (P, log-
rank =0.373). Median overall survival for stage IIA
was 3.6 years (95 % CI, 1.1 to 5.9 years), stage IIB
6.5 years (95 % CI, 0.7 years to non-estimable), stage
III 1.42 years (95 % CI, 0.4 to 3.6 years), and stage
IVA 1.6 years (95 % CI, 1.07 to 6.6 years). There
was no significant difference in the overall survival
rate of patients with adenocarcinoma and patients
with squamous cell carcinoma (data not shown).
When compared to patients without a pathological
complete response, those with a pathological complete
response had a statistically significant increase in median
survival (5.7 vs. 1.6 years, respectively, P, log-rank =
0.029) and progression-free survival (3.5 vs. 1.0 years, re-
spectively, P, log-rank = 0.030) (Fig. 3a and b). In an ex-
ploratory analysis, we used pathological staging defined
after surgical resection to segregate patients into four
groups: patients with (1) pathological complete response,
(2) microscopic residual disease or stage I, (3) stage II,
or (4) stage III/IV cancers. There was a statistically sig-
nificant difference in overall survival (p = 0.005) and pro-
gression free survival (p = 0.005) between each of these
four groups (Fig. 3c and d).
Of the 26 patients with recurrent disease, at the time
of initial detection of recurrence, 20 patients had distant
recurrence (77 %), six patients had local recurrence
(23 %), and one patient had simultaneous distant and
local recurrence. Three of the six patients with local re-
currence had received attenuated chemoradiation and
one patient with local recurrence had refused surgery.
Two of the 26 recurrences occurred five or more years
after enrollment. One patient developed metastatic
supraclavicular and mediastinal lymphadenopathy
5.1 years after enrollment and the other patient devel-
oped a metastatic lung lesion 6.8 years after enrollment.
Both recurrences were biopsied and confirmed to be re-
current esophageal cancer.
At the time of final analysis, five of the 40 patients
(12.5 %) were still alive at 9.6 years to 11 years since en-
rollment. Four of these five survivors had a complete re-
sponse to neoadjuvant chemoradiation.




























































Fig. 1 Kaplan-Meier estimates of overall survival (a) and progression
free survival (b) for all 40 patients enrolled in the trial































Fig. 2 Kaplan-Meier estimates of overall survival for all 40 patients
by pretreatment (clinical) stage (AJCC, 5th Edition)
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Incidence of brain metastases
Brain metastases developed in 6 of the 40 patients on this
trial (15 %) and were the first site of recurrence in four of
these patients. Consistent with the standard of care, base-
line brain imaging and routine CNS surveillance was not
utilized on this trial. However, one patient’s cerebellar me-
tastasis was detected on a surveillance PET/CT scan. All
of the other patients’ brain metastases were discovered be-
cause the patients presented with symptoms suspicious
for brain metastases.
Brain metastases occurred a median of 13.9 months
after surgery (range, 8.0 to 31.1 months). Brain metasta-
ses were seen in 5 of 34 patients (15 %) with adenocar-
cinoma and 1 of 6 patients (17 %) with squamous cell
carcinoma. The patient with squamous cell carcinoma
had a tumor that originated in the middle of the esopha-
gus, while all of the adenocarcinoma patients had tu-
mors that originated in the distal esophagus. Three of
the six patients (50 %) with brain metastases had an ex-
cellent response to neoadjuvant chemoradiation - with
either a complete pathological response (two patients) or
microscopic residual disease (one patient). Traditional
risk factors for recurrence, including clinical stage, op-
erative stage, or differentiation did not appear to predict
metastases to the brain.
Discussion
In this phase II trial, patients with locally advanced surgi-
cally resectable esophageal cancer received neoadjuvant
chemoradiation using cisplatin/irinotecan in conjuction
with celecoxib. The addition of celecoxib to the neoadju-
vant cisplatin/irinotecan chemoradiation appeared to be
well tolerated. The toxicity profile for patients treated with
the combination of celecoxib with neoadjuvant irinote-
can/cisplatin chemoradiation was similar to that seen in
prior trials of neoadjuvant chemoradiation with irinotecan
and cisplatin [13, 14].
Two previous studies examined neoadjuvant chemora-
diation with cisplatin and irinotecan in patients with lo-
cally advanced, resectable esophageal cancer and reported
a pathologic complete response rate of 16 % [13, 14].
While the addition of celecoxib to this regimen in our trial
found a higher pathologic complete response rate
(32.5 %), the median survival in our patients treated with
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Fig. 3 Kaplan-Meier estimates of overall survival (a) and progression free survival (b) in patients with and without a complete pathologic complete
response. c and d are Kaplan-Meier estimates of overall surival (c) and progression free survival (d) of four groups based on pathologic staging (AJCC,
5th Edition). The four groups are patients with a pathologic complete response, microscopic residual disease or stage I, stage II, or stage III/IV cancers
by pathologic staging
Cleary et al. BMC Cancer  (2016) 16:468 Page 6 of 9
concurrent celecoxib (34.7 months) was comparable to
the results for neoadjuvant chemoradiation with cisplatin
and irinotecan alone (31.7 and 36 months) [13, 14]. When
our trial was initially designed, we felt a pathologic
complete response rate of 25 % would be a promising re-
sult. However, pathologic complete response rate is a sur-
rogate end-point and overall survival is clearly the most
important measure of success. The survival rate in our
trial is comparable to that of historical controls. These re-
sults would suggest that addition of celecoxib to this che-
moradiation regimen is unlikely to meaningfully improve
the efficacy of neoadjuvant chemoradiation with cisplatin/
irinotecan.
There have been several other trials that have exam-
ined the addition of celecoxib to neoadjuvant treatment
in esophageal cancer (Table 4) [31–33]. Similar to our
results, all of these trials found that the addition of cele-
coxib to neoadjuvant therapy was well tolerated. How-
ever, Altorki et al. noted that the rate of venous
thromboembolic events was higher than expected in the
perioperative period [31].
Consistent with our results, the only phase 2
esophageal cancer study examining celecoxib in com-
bination with neoadjuvant chemoradiation concluded
that the addition of celecoxib did not increase the effi-
cacy of the chemoradiation [32]. Another study, examin-
ing neoadjuvant carboplatin/paclitaxel chemotherapy
combined with celecoxib, met its primary endpoint
by achieving complete pathological response and/or
minimal residual disease in 12.8 % of its patients
[31]. In an unplanned post-hoc analyses, this study
found that COX2 expressing tumors had higher rates
of major pathological response and improved overall
survival [31].
Increased COX2 expression in esophageal cancer has
been associated decreased survival [20–22, 34]. Preclinical
models have demonstrated that COX2 may play a func-
tional role in the malignant transformation from Barrett’s
esophagus to esophageal adenocarcinoma [23, 24, 35, 36].
Multiple reports have suggested that cyclooxygenase in-
hibitors (COX inhibitors) decrease the risk of esophageal
cancer [37–39]. One recent meta-analysis showed that
COX inhibitors reduce the risk of developing esophageal
adenocarcinoma by 30 % [40]. In addition, several preclin-
ical studies have shown that the selective COX2 inhibitor
celecoxib works synergistically with radiation to increase
cancer cell death [25, 26, 41]. Multiple reports have dem-
onstrated that high expression of COX2 correlates with
decreased responsiveness to radiation [27–29, 42]. None-
theless, despite these encouraging preclinical data and ob-
servational studies in humans, we do not find a clear
survival benefit when comparing our regimen combining
celecoxib with cisplatin/irinotecan chemoradiation to
prior trials of cisplatin/irinotecan chemoradiation alone.
A major strength of our trial is the availability of long-
term follow-up data. The three- and five-year survival
rates, 47.5 and 30 % respectively, seen in our study appear
comparable to other studies [43, 44]. Highlighting the im-
portance of neoadjuvant chemoradiation, the five long-
term surviving patients in our study all had an excellent
response to chemoradiation. Four of the five patients
(80 %) had a complete response to chemoradiation and
the other patient’s tumor was downsized to T1N0. In fact,
pathologic staging at the time of surgery was a significant
predictor of both progression free survival and overall sur-
vival (Fig. 3c and d).
A weakness of this paper is that it utilizes cisplatin/iri-
notecan chemoradiation. While neoadjuvant cisplatin/
irinotecan chemoradiation was a commonly used regi-
men at the time this study was conducted, since the
publication of the CROSS trial, the standard of care has
been carboplatin and paclitaxel [10]. Another limitation
of this trial is that it is a single arm 40 patient study. An
additional weakness of this study is that there is no data
about celecoxib compliance.
Despite the notion that the brain represents an un-
common site of metastasis in esophageal cancer, 15 %
of patients enrolled in our trial developed brain metas-
tases during follow-up. While a series of 1588 esopha-
geal cancer patients found only a 1.7 % prevalence of
brain metastases [45], more recent series that exam-
ined the incidence of brain metastases following neo-
adjuvant or adjuvant treatment for esophageal cancer
reported rates of 13 to 18 % [46, 47]. Of note, in the
Table 4 Trials Testing Preoperative Celecoxib in Esophageal Cancer
Study Phase Regimen Patients Conclusion
Dawson et al. [33] 1 5-FU/Cisplatin Chemoradiation Combined
with Celecoxib
13 Regimen was well tolerated. The study was closed early
because of external safety concerns regarding Celecoxib.
Altorki et al. [31] 2 Carboplatin/Paclitaxel Chemotherapy
Combined with Celecoxib
39 Regimen was well tolerated with the exception of the
fact that the rate perioperative venous thromboembolic
events was higher than expected. Patients with tumors
that expressed COX2 demonstrated higher rates of major
pathological response and improved overall survival.
Govindan et al. [32] 2 5-FU/Cisplatin Chemoradiation Combined
with Celecoxib
31 Regimen was well tolerated. The pathological complete
response rate of 5-FU/Cisplatin/Celecoxib chemoradiation
was similar to historical controls.
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current trial, response to neoadjuvant therapy did not
predict the development of brain metastases.
Conclusion
In conclusion, the addition of celecoxib did not appear
meaningfully improve the efficacy of neoadjuvant che-
moradiation in an unselected population of locally ad-
vanced esophageal cancer patients. Given the high rate
of recurrence and poor outcome in this patient popula-
tion, future studies need to define more effective neoad-
juvant and adjuvant regimens.
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